F. Hoffmann-La Roche has been granted a patent for a combination therapy for treating hepatitis B virus infection. The therapy involves administering a TLR7 agonist and an HBV capsid assembly inhibitor to chronic hepatitis B patients. The pharmaceutical composition includes a compound of formula (I) as the TLR7 agonist. GlobalData’s report on F. Hoffmann-La Roche gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on F. Hoffmann-La Roche, Cancer treatment biomarkers was a key innovation area identified from patents. F. Hoffmann-La Roche's grant share as of September 2023 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Combination therapy for treating hepatitis b virus infection
A recently granted patent (Publication Number: US11771699B2) discloses a pharmaceutical composition for the treatment or prophylaxis of hepatitis B virus (HBV) infection. The composition comprises a Toll-like receptor 7 (TLR7) agonist and an HBV capsid assembly inhibitor in a pharmaceutically acceptable carrier. The TLR7 agonist is a compound of formula (I) and can be selected from various specific compounds listed in the claims. The HBV capsid assembly inhibitor is a specific compound listed in the claims. The composition may also include one or more other antiviral agents such as lamivudine, adefovir, tenofovir, telbivudine, or entecavir.
The patent also describes a kit comprising the TLR7 agonist and the HBV capsid assembly inhibitor in a container, along with a sterile diluent and a package insert providing instructions for use. The kit can be used for the treatment or prophylaxis of HBV infection.
In addition, the patent claims a method for the treatment or prophylaxis of HBV infection. The method involves administering an effective amount of the TLR7 agonist and the HBV capsid assembly inhibitor to a subject. The TLR7 agonist and the HBV capsid assembly inhibitor can be administered simultaneously or sequentially, and they can be administered in the same formulation or different formulations. The method may also involve administering one or more other antiviral agents such as lamivudine, adefovir, tenofovir, telbivudine, or entecavir.
Overall, this patent provides a pharmaceutical composition, a kit, and a method for the treatment or prophylaxis of HBV infection using a combination of a TLR7 agonist and an HBV capsid assembly inhibitor. These inventions have the potential to improve the management of HBV infection and may offer new therapeutic options for patients.
To know more about GlobalData’s detailed insights on F. Hoffmann-La Roche, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
